Avances en la inmunosupresión para el trasplante renal: Nuevas estrategias para preservar la función renal y reducir el riesgo cardiovascular

the development of new immunosuppressants for renal transplantation is aimed not only at improving short-term outcomes, but also at achieving better safety, cardiovascular, and metabolic profiles and at decreasing nephrotoxicity. belatacept is a fusion protein that inhibits t cell activation by binding to cd80 and cd86 antigens. clinical trials, particularly the benefit and benefit-ext studies, have shown that belatacept preserves function and structure in renal grafts. the effects of belatacept provide long-term, sustained results, and the safety and efficacy of this drug have been demonstrated in cases of renal transplantation from expanded criteria donors. compared to calcineurin inhibitors, belatacept is associated with a lower incidence of chronic allograft nephropathy and a more favourable cardiovascular and metabolic profile.